12/08/2024
🚀 Celebrating a Major Milestone – Series A Funding Closed! 🚀
We are excited to share that PL BioScience has successfully closed our Series A financing round, securing an impressive €7.8 million! This significant milestone wouldn’t have been possible without the trust and support of our renowned investors.
A big thank you to the investors who believe in our vision:
- AVANT BIO
- LePure Biotech
- b.value AG
- better ventures
- Brightlands Venture Partners
- TechVision Fonds
Derived from upcycled donated blood, Human Platelet Lysate (HPL) offers a more ethical, sustainable and animal-free alternative to traditional cell culture media supplements. With this funding, we will be able to expand our production capabilities and solidify our position as a world-class provider of HPL, accelerating the innovations are developing within our product portfolio, and ensuring stable supply to researchers worldwide. 🧪🌎
Of course, none of this would be possible without the dedication of the PL BioScience team. Everyone’s passion and hard work continues to drive us forward. Together, we are helping to shape a xeno-free cell culture future!
Lastly, from all of us in Aachen to all our customers and partners around the world, thank you for your continued support and trust in us. As we enter this new chapter of our company journey, we are excited to reach new heights with everyone! 🌟
Read more in the press release: https://www.startbase.com/news/pl-bioscience-sichert-78-millionen-euro-in-series-a-finanzierung/?utm_source=hootsuite&utm_medium=Facebook&utm_term=&utm_content=&utm_campaign=SeriesAPressRelease
Aachen cell culture solution promotes global growth in the field of cell therapy.